Peptides
Survodutide Peptide for Weight Loss
Dosage calculator available
Reconstitution & dosing math for Survodutide.
01
Quick Facts
| Quick Facts | Details |
|---|---|
| Also Known As | BI 456906 |
| Class | Dual GLP-1/glucagon receptor agonist |
| Structure | 29-amino-acid peptide |
| GLP-1:Glucagon Ratio | 8:1 |
| Half-life | 109-115 hrs (once-weekly SC) |
| Research/Approval Stage | Investigational; FDA Fast Track Designation 2021 for MASH |
02
The Mechanism Deep Dive
- Half-life of 109-115 hrs, supporting once-weekly subcutaneous dosing.
- Albumin binding via a C18 diacid.
- GLP-1 receptor activity acts on the hypothalamus and hindbrain (POMC/CART up, NPY/AgRP down).
- Glucagon receptor activity drives hepatic FGF21, brown-fat UCP, and mitochondrial biogenesis.
03
Clinical Trial Results — Obesity Study
Reconstructed from the values stated in the source. Phase II obesity trial (387 patients, BMI ≥27, 46 weeks); no plateau observed.
| Dose | Body Weight Reduction (46 weeks) |
|---|---|
| 0.6 mg | -6.2% |
| 2.4 mg | -12.5% |
| 3.6 mg | -13.2% |
| 4.8 mg | -14.9% |
| Placebo | -2.8% |
04
Clinical Trial Results — Type 2 Diabetes
- HbA1c reduced by 1.5% versus placebo over 16 weeks.
- High-dose produced up to 8.7% weight loss.
05
Clinical Trial Results — MASH/NASH
- 48-week Phase II: 83% MASH improvement without worsening of fibrosis.
- 63-67% achieved ≥30% liver-fat reduction.
- 34-36% showed fibrosis improvement of ≥1 stage.
- Highest dose achieved 62% liver-fat reduction.
06
Side Effects and Safety Profile
Approximately 90.9% of the treatment group experienced adverse events, mostly gastrointestinal. Reductions in blood pressure and triglycerides were also observed.
Reconstructed from the values stated in the source.
| Adverse Event | Survodutide | Placebo |
|---|---|---|
| Nausea | 66% | 23% |
| Diarrhea | 49% | 23% |
| Vomiting | 41% | 4% |
| Serious adverse events | 4.2% | 6.5% |
07
How Survodutide Stacks Up
Reconstructed from the values stated in the source.
| Treatment | Weight Reduction |
|---|---|
| Survodutide | 14.9-18.7% / 46 wk |
| Semaglutide | 12-14% |
| Tirzepatide | up to 20% / 72 wk |
| Liraglutide | 8-10% |
| Orlistat | 5-7% |
| Bariatric surgery | 25-30% |
08
What's Coming Down the Pipeline
- Investigational; FDA Fast Track Designation granted in 2021 for MASH.
- SYNCHRONIZE Phase III program comprises 5 trials, including SYNCHRONIZE-CVOT (4,935 patients) and SYNCHRONIZE-JP/CN.
- Possible approval in 2-3 years.
09
Practical Application Guide — Dosing
- Weeks 1-2: 0.6 mg subcutaneously weekly, then titrate through 1.2 mg, 1.8 mg, and 2.4 mg.
- From week 9 onward: titrate to 3.6-4.8 mg.
- Community-reported sweet spot: 2.4-3.6 mg.
10
Practical Application Guide — Storage
- Store lyophilized product at 2-8°C.
- Use reconstituted product within 28 days.
- Administer with insulin syringes and rotate injection sites.
11
Practical Application Guide — Optimization Stack
- Berberine 500 mg twice daily.
- Ginger 250 mg.
- Electrolytes.
- Metformin (under supervision).
References
- 01Diabetes.org — https://diabetes.org/newsroom/late-breaking-weight-loss-innovations...
- 02PubMed — https://pubmed.ncbi.nlm.nih.gov/38095657/
- 03HCPLive — https://www.hcplive.com/view/survodutide-improves-mash-without-worsening-of-fibrosis-reduces-liver-fat
- 04Auctores (mechanism source) — https://auctoresonline.org/article/survodutide-a-promising-agent...
This profile is being expanded — additional sections from the source are still being added.
Related in the library